Ep. 79 - Flemming Ørnskov on Building the World’s Largest Independent Global Dermatology Company

Galderma recently made national headlines with a new neurotoxin that promises rapid onset and long duration up to 6 months — and while that may sound too good to be true, the data comes directly from two phase III clinical studies.If that were the only news Galderma CEO Flemming Ørnskov had for us, it would be worthy of an episode in itself. But in this interview with Dr. Grant Stevens, he announces that Galderma will be launching a total of 22 new products this year alone!Tune in to hear all this and more on the latest episode of The Technology of Beauty.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/